Table 1 Baseline demographic and clinical characteristics
Characteristics | All patients (n = 222) |
|---|---|
Age, years (mean ± sd) | 66.90 ± 9.62 |
 < 65, n (%) | 85 (39.10%) |
 65–75, n (%) | 94 (41.82%) |
 > 75, n (%) | 43 (19.10%) |
Male, n (%) | 171 (77.03%) |
BMI (kg/m2) | 26.10 ± 3.90 |
AF Duration, year | 4 (1—10) |
nPAF, n (%) | 158 (71.17%) |
Pre-procedure OAC use, n(%) | 166 (74.77%) |
Comorbidity | Â |
 Hypertension, n (%) | 156 (70.27%) |
 Heart Failure, n (%) | 26 (11.71%) |
 HCM, n (%) | 11 (4.95%) |
 Diabetes mellitus, n (%) | 61 (27.48%) |
 Stroke/TIA, n (%) | 155 (69.82%) |
 Systemic thromboembolism, n (%) | 15 (6.76%) |
 CAD, n (%) | 58 (26.13%) |
 PAD, n (%) | 36 (16.22%) |
 PCI, n (%) | 23 (10.36%) |
 CABG, n (%) | 7 (3.15%) |
 CKD, n (%) | 13 (5.86%) |
 Dialysis, n (%) | 3 (1.35%) |
Previous LAA thrombus, n (%) | 18 (8.49%) |
CHA2DS2-VASc score | 3.78 ± 1.49 |
 0, n (%) | 3 (1.35%) |
 1, n (%) | 11 (4.95%) |
 2, n (%) | 31 (13.96%) |
 3, n (%) | 45 (20.27%) |
 4, n (%) | 62 (27.93%) |
 5, n (%) | 46 (20.72%) |
 6, n (%) | 16 (7.21%) |
 7, n (%) | 7 (3.15%) |
 8, n (%) | 1 (0.45%) |
Hemorrhage* | |
 Cerebral, n (%) | 30 (13.51%) |
 Gastrointestinal, n (%) | 20 (9.01%) |
 Other, n (%) | 4 (1.80%) |
HAS-BLED score | 1.68 ± 0.86 |
 0, n (%) | 11 (4.95%) |
 1, n (%) | 89 (40.09%) |
 2, n (%) | 88 (39.64%) |
 3, n (%) | 29 (13.06%) |
 4, n (%) | 4 (1.80%) |
 5, n (%) | 1 (0.45%) |
Transthoracic echocardiography | |
 LA, mm | 43.46 ± 5.63 |
 RA, mm | 44.09 ± 6.01 |
 LVEDD, mm | 48.00 ± 5.22 |
 LVPW, mm | 9.59 ± 1.97 |
 IVS, mm | 10.42 ± 2.16 |
 LVEF, % | 61.04 ± 7.99 |
 MR, n (%) | |
  Moderate | 25 (11.63%) |
  Severe | 5 (2.33%) |
 TR, n (%) | |
  Moderate | 35 (16.28%) |
  Severe | 16 (7.44%) |
LAA ostium diameter (mm) | |
 TEE | 22.95 ± 4.15 |
 DSA | 22.89 ± 3.82 |